Uncomplicated reticular veins treatment* (1-3 mm) 
Results at 4 weeks after last treatment.
*Individual results may vary depending on varicose vein severity, disease progression, skin tone, and number of treatments.

Asclera® (polidocanol) Injection is indicated to sclerose uncomplicated spider veins (varicose veins ≤1 mm in diameter) and uncomplicated reticular veins (varicose veins 1 to 3 mm in diameter) in the lower extremity. Asclera® has not been studied in varicose veins more than 3 mm in diameter.

IMPORTANT SAFETY INFORMATION:
For intravenous use only.

CONTRAINDICATIONS: Asclera® (polidocanol) Injection is contraindicated for patients with known allergy (anaphylaxis) to polidocanol and patients with acute thromboembolic diseases. (Important Safety Information continued on next page)
CLINICAL RESULTS

Asclera® was evaluated in a multicenter, randomized, double-blind, placebo and comparator-controlled trial (EASI-study) in patients with spider or reticular varicose veins. A total of 338 Caucasian patients, who were predominantly female, were treated with Asclera® [0.5% for spider veins (n=94), 1% for reticular veins (n=86), sodium tetradecyl sulfate (STS) 1% (n=105), or placebo (0.9% isotonic saline solution) (n=53)] for either spider or reticular veins. Patients received an intravenous injection in the first treatment session; repeat injections were given three and six weeks later if the previous injection was evaluated as unsuccessful (defined as 1, 2, or 3 on a 5-point scale).

Patients returned at 12 and 26 weeks after the last injection for final assessments. The primary effectiveness endpoint was improvement of veins judged by a blinded panel. Digital images of the selected treatment area were taken prior to injection, compared with those taken at 12 weeks post-treatment, and rated on a 5-point scale (1 = worse than before, 2 = same as before, 3 = moderate improvement, 4 = good improvement, 5 = complete treatment success).

**TREATMENT SUCCESS**

- 95% of patients treated with Asclera® showed good improvement or complete treatment success as rated by physicians
- Asclera® results were statistically significant when compared to placebo (p<0.0001) for the primary efficacy criterion “improvement of veins”

![TREATMENT SUCCESS RATES](chart)

^Treatment success: Yes = Grade 4 to 5, No = Grade 1 to 3; derived from median of evaluation.

IMPORTANT SAFETY INFORMATION (Continued):

WARNINGS AND PRECAUTIONS:

Anaphylaxis: Severe allergic reactions have been reported following polidocanol use, including anaphylactic reactions, some of them fatal. Severe reactions are most frequent with use of larger volumes (> 3 mL). The dose of polidocanol should therefore be minimized. Be prepared to treat anaphylaxis appropriately.
CONSISTENCY OF COMPOUNDED POLIDOCANOL SOLUTIONS*1

- Compounded polidocanol solutions did not deliver the claimed concentration five out of six times
- The GC/MS analysis showed impurities in all six compounded solutions

PATIENT SATISFACTION*

In the EASI-study (referenced on previous page):

- 87% of patients were satisfied or very satisfied with their Asclera® treatment
- Patients were significantly more satisfied with Asclera® than with either STS or placebo (p<0.0001)

*Six samples of 1% polidocanol solutions obtained from four compounding pharmacies were evaluated using gas chromatography mass spectrometry (GC/MS) assays for POL concentrations and identification of material impurities.

IMPORTANT SAFETY INFORMATION (Continued):

WARNINGS AND PRECAUTIONS (Continued):

Accidental Intra-arterial injection can cause severe necrosis, ischemia or gangrene. If this occurs, consult a vascular surgeon immediately.

Inadvertent Perivascular Injection of Asclera® can cause pain. If pain is severe, a local anesthetic (without adrenaline) may be injected.
Individual results may vary depending on varicose vein severity, disease progression, skin tone, and number of treatments.

UNCOMPLICATED SPIDER VEINS TREATMENTS* (<1 MM)

Results at 4 weeks after last treatment

Results at 4 weeks after last treatment

Results at 26 weeks after last treatment

*Individual results may vary depending on varicose vein severity, disease progression, skin tone, and number of treatments.

IMPORTANT SAFETY INFORMATION (Continued):

WARNINGS AND PRECAUTIONS (Continued):

Severe adverse local effects, including tissue necrosis, may occur following extravasation; therefore, take care in intravenous needle placement and the smallest effective volume at each injection site should be used.

After the injection session is completed, apply compression with a stocking or bandage, and have the patient walk for 15-20 minutes. Keep the patient under supervision during this period to treat any anaphylactic or allergic reactions.

Maintain compression for 2 to 3 days after treatment of spider veins and for 5 to 7 days for reticular veins. For extensive varicosities, longer compression treatment with compression bandages or a gradient compression stocking of a higher compression class is recommended. Post-treatment compression is necessary to reduce the risk of deep vein thrombosis.
Individual results may vary depending on varicose vein severity, disease progression, skin tone, and number of treatments.

Results at 4 weeks after last treatment

Results at 18 weeks after last treatment

Results at 26 weeks after last treatment

*Individual results may vary depending on varicose vein severity, disease progression, skin tone, and number of treatments.

**Asclera® (Polidocanol) Injection: A Proven Treatment for Uncomplicated Spider and Uncomplicated Reticular Veins**

**Important Safety Information (Continued):**

**Adverse Reactions:** In clinical studies, the following adverse reactions were observed after using Asclera® and were more common with Asclera® than placebo: injection site hematoma, injection site irritation, injection site discoloration, injection site pain, injection site pruritus, injection site warmth, neovascularization, injection site thrombosis.
ORDER ASCLERA® TODAY!

Call customer service at 866-862-1211.

PROVEN STABILITY

- 3 year manufacturer shelf life
- Stable at room temperature
- Single dose ampule

ORDERING INFORMATION

<table>
<thead>
<tr>
<th>DESCRIPTION</th>
<th>PART NUMBER</th>
<th>NDC</th>
</tr>
</thead>
<tbody>
<tr>
<td>Asclera® (polidocanol) Injection 0.5%</td>
<td>7220121</td>
<td>46783-121-52</td>
</tr>
<tr>
<td>Asclera® (polidocanol) Injection 1%</td>
<td>7220221</td>
<td>46783-221-52</td>
</tr>
</tbody>
</table>

MERZ AESTHETICS™


Copyright © 2012 Merz Aesthetics, Inc. All rights reserved. Asclera is a registered trademark of Chemische Fabrik Kreussler & Co., GmbH. MERZ AESTHETICS and the Merz Aesthetics logo are trademarks of Merz Pharma GmbH & Co. KGaA.

EM00557-00